Quantitating therapeutic disruption of tumor blood flow with intravital video microscopy

被引:9
作者
Iga, Arthur M.
Sarkar, Sandip
Sales, Kevin M.
Winslet, Marc C.
Seifalian, Alexander M.
机构
[1] UCL, Acad Div Surg & Intervent Sci, GI & Hepatobiliary Res Unit, London NW3 2PF, England
[2] Royal Free Hampstead NHS Trust Hosp, Dept Surg, London, England
关键词
D O I
10.1158/0008-5472.CAN-06-1743
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Vascular-disrupting agents (VDA) kill tumor cells by selectively disrupting blood circulation in tumors. In vivo analysis of this intensely studied class of anticancer agents is invaluable for preclinical assessment of pharmacodynamic end points and effective therapeutic windows. In this review, we consider the role of intravital video microscopy in measuring tumor vascular response to VDAs, the potential of which lies in the opportunity to quantitate specific variables and to obtain real-time information on how VDAs affect tumor microcirculation.
引用
收藏
页码:11517 / 11519
页数:3
相关论文
共 20 条
[1]   Antivascular therapy of cancer: DMXAA [J].
Baguley, BC .
LANCET ONCOLOGY, 2003, 4 (03) :141-148
[2]   COMPARISON OF THE EFFECTS OF FLAVONE ACETIC-ACID, FOSTRIECIN, HOMOHARRINGTONINE AND TUMOR NECROSIS FACTOR-ALPHA ON COLON-38 TUMORS IN MICE [J].
BAGULEY, BC ;
CALVELEY, SB ;
CROWE, KK ;
FRAY, LM ;
OROURKE, SA ;
SMITH, GP .
EUROPEAN JOURNAL OF CANCER & CLINICAL ONCOLOGY, 1989, 25 (02) :263-269
[3]   Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance [J].
Boehm, T ;
Folkman, J ;
Browder, T ;
OReilly, MS .
NATURE, 1997, 390 (6658) :404-407
[4]  
Dark GG, 1997, CANCER RES, V57, P1829
[5]  
Davis PD, 2002, CANCER RES, V62, P7247
[6]   Effects of 5,6-dimethylxanthenone-4-acetic acid on human tumor microcirculation assessed by dynamic contrast-enhanced magnetic resonance imaging [J].
Galbraith, SM ;
Rustin, GJS ;
Lodge, MA ;
Taylor, NJ ;
Stirling, JJ ;
Jameson, M ;
Thompson, P ;
Hough, D ;
Gumbrell, L ;
Padhani, AR .
JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (18) :3826-3840
[7]   Vascular disrupting agents: A new class of drug in cancer therapy [J].
Gaya, AM ;
Rustin, GJS .
CLINICAL ONCOLOGY, 2005, 17 (04) :277-290
[8]   Microvascular mechanisms by which the combretastatin A-4 derivative AC7700 (AVE8062) induces tumour blood flow stasis [J].
Hori, K ;
Saito, S .
BRITISH JOURNAL OF CANCER, 2003, 89 (07) :1334-1344
[9]   Antitumor and antivascular effects of AC-7700, a combretastatin A-4 derivative, against rat liver cancer [J].
Ohno T. ;
Kawano K. ;
Sasaki A. ;
Aramaki M. ;
Tahara K. ;
Etoh T. ;
Kitano S. .
International Journal of Clinical Oncology, 2002, 7 (3) :171-176
[10]  
Read TA, 2001, CANCER RES, V61, P6830